MAPT and Alzheimer disease: In parallel studies on cohorts of AD patients, we and others have evidenced the association between irisin levels in the cerebrospinal fluid (CSF) and AD biomarkers, such as amyloid‐β (Aβ) and tau proteins [11, 12].